Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Treatments: Capecitabine; Mitomycin; Mitomycins

Criteria

Inclusion Criteria:

• CT/MRI diagnosed stage cT1-4N0-3;

• Histologically confirmed anal squamous carcinoma;

• KPS >= 70

• Adequate organ function;

• No previous radiotherapy or chemotherapy;

• No surgery.

Exclusion Criteria:

• Previous malignant cancer history;

• Allegic to 5-fu or MMC